Gene therapy for hemophilia: Current status and laboratory consequences

17Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Since the cloning and characterization of the factor VIII (FVIII) and factor IX genes in the mid-1980s, gene therapy has been perceived as having significant potential for the treatment of severe hemophilia. Now, some 35 years later, these proposals are close to being realized through the licensing of the first clinical gene therapy product. Adeno-associated viral vector-mediated gene therapy for hemophilia A and B has been extensively investigated in preclinical models over the past 20 years, and since 2011, there has been increasing evidence in early phase clinical trials that this therapeutic strategy can provide safe and effective rescue of the hemostatic phenotype in severe hemophilia. As the uptake of hemophilia gene therapy progresses, it is clear that many aspects of the gene therapy process require crucial laboratory support to ensure safe and effective outcomes from his new therapeutic paradigm. These laboratory contributions extend from evaluations of the gene therapy vehicle, assessments of the patient immune status for the vector, and ultimately the performance of assays to determine the hemostatic benefit of the gene therapy and potentially of its long-term safety on the host genome. As with many aspects of past hemophilia care, the safe and effective delivery of gene therapy will require an informed and coordinated contribution from laboratory science.

References Powered by Scopus

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

1558Citations
N/AReaders
Get full text

Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics

1133Citations
N/AReaders
Get full text

Long-term safety and efficacy of factor IX gene therapy in hemophilia B

1077Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The Arrival of Gene Therapy for Patients with Hemophilia A

18Citations
N/AReaders
Get full text

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments

16Citations
N/AReaders
Get full text

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Batty, P., & Lillicrap, D. (2021, July 1). Gene therapy for hemophilia: Current status and laboratory consequences. International Journal of Laboratory Hematology. John Wiley and Sons Inc. https://doi.org/10.1111/ijlh.13605

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

63%

Researcher 5

31%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 5

45%

Medicine and Dentistry 3

27%

Chemistry 2

18%

Chemical Engineering 1

9%

Save time finding and organizing research with Mendeley

Sign up for free